Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2014

Open Access 01-12-2014 | Research

Association of social and cognitive impairment and biomarkers in autism spectrum disorders

Authors: Altaf Alabdali, Laila Al-Ayadhi, Afaf El-Ansary

Published in: Journal of Neuroinflammation | Issue 1/2014

Login to get access

Abstract

Objectives

The neurological basis for autism is still not fully understood, and the role of the interaction between neuro-inflammation and neurotransmission impairment needs to be clearer. This study aims to test the possible association between impaired levels of gamma aminobutyric acid (GABA), serotonin, dopamine, oxytocin, and interferon-γ-induced protein-16 (IFI16) and the severity of social and cognitive dysfunctions in individuals with autism spectrum disorders.

Materials and methods

GABA, serotonin, dopamine, oxytocin, and IFI16 as biochemical parameters related to neurochemistry and inflammation were determined in the plasma of 52 Saudi autistic male patients, categorized as mild-moderate and severe as indicated by their Childhood Autism Rating Scale (CARS) or social responsiveness scale (SRS), and compared to 30 age- and gender-matched control samples.

Results

The data indicated that Saudi patients with autism have remarkably impaired plasma levels of the measured parameters compared to age and gender-matched controls. While serotonin in platelet-free plasma and dopamine did not correlated with the severity in social and cognitive dysfunction, GABA, oxytocin, and IFI16 were remarkably associated with the severity of both tested scores (SRS and CARS).

Conclusions

The relationship between the selected parameters confirms the role of impaired neurochemistry and neuro-inflammation in the etiology of autism spectrum disorders and the possibility of using GABA, oxytocin, and IFI16 as markers of autism severity. Receiver operating characteristic analysis together with predictiveness diagrams proved that the measured parameters could be used as predictive biomarkers of clinical symptoms and provide significant guidance for future therapeutic strategy to re-establish physiological homeostasis.
Appendix
Available only for authorised users
Literature
1.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 2000, Washington, DC: American Psychiatric Association, 4
2.
Esposito G, Venuti P: Analysis of toddlers’ gait after six months of independent walking to identify autism: a preliminary study. Percept Mot Skills. 2008, 106 (1): 259-269. 10.2466/pms.106.1.259-269.CrossRefPubMed
3.
Lord C, Rutter M, le Couteur A: Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994, 24 (5): 659-685. 10.1007/BF02172145.CrossRefPubMed
4.
Baranek G: Sensory and motor features in autism: assessment and intervention. Handbook of Autism and Pervasive Developmental Disorders. Edited by: Volkmar FR, Paul R, Klin A, Cohen D. 2005, Hoboken NJ: John Wiley & Sons Inc, 831-857. 3
5.
Ozonoff S, Young GS, Goldring S, Greiss-Hess L, Herrera AM, Steele J, Macari S, Hepburn S, Rogers SJ: Gross motor development, movement abnormalities, and early identification of autism. J Autism Dev Disord. 2008, 38 (4): 644-656. 10.1007/s10803-007-0430-0.PubMedCentralCrossRefPubMed
6.
Esposito G, Venuti P, Maestro S, Muratori F: An exploration of symmetry in early autism spectrum disorders: analysis of lying. Brain Dev. 2009, 31 (2): 131-138. 10.1016/j.braindev.2008.04.005.CrossRefPubMed
7.
Pizzarelli R, Cherubini E: Alterations of GABAergic signaling in autism spectrum disorders. Neural Plast. 2011, Article ID: 297153.
8.
Rogers SJ, Vismara LA: Evidence-based comprehensive treatments for early autism. J Clin Child Adolesc Psychol. 2008, 37: 8-38. 10.1080/15374410701817808.PubMedCentralCrossRefPubMed
9.
Kałuzna-Czaplińska J, Socha E, Rynkowski J: Determination of homovanillic acid and vanillylmandelic acid in urine of autistic children by gas chromatography/mass spectrometry. Med Sci Monit. 2010, 16 (9): 445-450.
10.
Hammock E, Veenstra-VanderWeele J, Yan Z, Kerr TM, Morris M, Anderson GM, Carter CS, Cook EH, Jacob S: Examining autism spectrum disorders by biomarkers: example from the oxytocin and serotonin systems. J Am Acad Child Adolesc Psychiatry. 2012, 51 (7): 712-721. 10.1016/j.jaac.2012.04.010.PubMedCentralCrossRefPubMed
11.
Anderson GM, Hertzig ME, McBride PA: Platelet-poor plasma serotonin in autism. J Autism Dev Disord. 2012, 42 (7): 1510-1514. 10.1007/s10803-011-1371-1.CrossRefPubMed
12.
El-Ansary AK, Bacha AB, Ayahdi LY: Relationship between chronic lead toxicity and plasma neurotransmitters in autistic patients from Saudi Arabia. Clin Biochem. 2011, 44: 1116-1120. 10.1016/j.clinbiochem.2011.06.982.CrossRefPubMed
13.
Fatemi SH, Folsom TD, Reutiman TJ, Thuras PD: Expression of GABA(B) receptors is altered in brains of subjects with autism. Cerebellum. 2009, 8 (1): 64-69. 10.1007/s12311-008-0075-3.PubMedCentralCrossRefPubMed
14.
Blatt GJ, Fatemi SH: Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications. Anat Rec (Hoboken). 2011, 294 (10): 1646-1652. 10.1002/ar.21252.CrossRef
15.
Kubas B, Kułak W, Sobaniec W, Tarasow E, Lebkowska U, Walecki J: Metabolite alterations in autistic children: a 1H MR spectroscopy study. Adv Med Sci. 2012, 57 (1): 152-156.CrossRefPubMed
16.
Al-Ayadhi LY: Altered oxytocin and vasopressin levels in autistic children in Central Saudi Arabia. Neurosciences (Riyadh). 2005, 10 (1): 47-50.
17.
Ragini M, Banji O, Banji D, Pratusha G, Kumar K, Ananthula MR: Biomarkers in Autism. Int J Pharm Tech Res. 2011, 3: 1281-1289.
18.
Haroon E, Raison CL, Miller AH: Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology. 2012, 37: 137-162. 10.1038/npp.2011.205.PubMedCentralCrossRefPubMed
19.
Leonard BE: Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2014, 48: 261-267.CrossRefPubMed
20.
Laurence JA, Fatemi SH: Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects. Cerebellum. 2005, 4: 206-210. 10.1080/14734220500208846.CrossRefPubMed
21.
Fatemi SH, Folsom TD, Reutiman TJ, Lee S: Expression of astrocytic markers aquaporin 4 and connexin 43 is altered in brains of subjects with autism. Synapse. 2008, 62: 501-507. 10.1002/syn.20519.PubMedCentralCrossRefPubMed
22.
Müller N, Schwarz MJ: The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry. 2007, 12: 988-1000. 10.1038/sj.mp.4002006.CrossRefPubMed
23.
Pacheco R, Gallart T, Lluis C, Franco R: Role of glutamate on T-cell mediated immunity. J Neuroimmunol. 2007, 185: 9-19. 10.1016/j.jneuroim.2007.01.003.CrossRefPubMed
24.
Coghlan S, Horder J, Inkster B, Mendez MA, Murphy DG, Nutt DJ: GABA system dysfunction in autism and related disorders: From synapse to symptoms. Neurosci Biobehav Rev. 2012, 36: 2044-2055. 10.1016/j.neubiorev.2012.07.005.PubMedCentralCrossRefPubMed
25.
Hussman JP: Suppressed GABAergic inhibition as a common factor in suspected etiologies of autism. J Autism Dev Disord. 2001, 31 (2): 247-248. 10.1023/A:1010715619091.CrossRefPubMed
26.
Fatemi SH, Folsom TD, Kneeland RE, Liesch SB: Metabotropic glutamate receptor 5 upregulation in children with autism is associated with underexpression of both Fragile X mental retardation protein and GABAA receptor beta 3 in adults with autism. Anat Rec (Hoboken). 2011, 294 (10): 1635-1645. 10.1002/ar.21299.CrossRef
27.
Singh VK: Plasma increase of interleukin-12 and interferon-gamma: pathological significance in autism. J Neuroimmunol. 1996, 66: 143-145. 10.1016/0165-5728(96)00014-8.CrossRefPubMed
28.
El-Ansary A, Ben Bacha AG, Al-Ayadhi LY: Proinflammatory and proapoptotic markers in relation to mono and di-cations in plasma of autistic patients from Saudi Arabia. J Neuroinflammation. 2011, 8: 142-10.1186/1742-2094-8-142.PubMedCentralCrossRefPubMed
29.
30.
31.
Boehm U, Klamp T, Groot M, Howard JC: Cellular responses to interferon-gamma. Annu Rev Immunol. 1997, 15: 749-795. 10.1146/annurev.immunol.15.1.749.CrossRefPubMed
32.
Mick KA: Diagnosing Autism: Comparison of the Childhood Autism Rating Scale (CARS) and the Autism Diagnostic Observation Schedule (ADOS).PhD Dissertation. 2005, Kansas: Wichita State University
33.
Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, Metzger LM, Shoushtari CS, Splinter R, Reich W: Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord. 2003, 33: 427-433. 10.1023/A:1025014929212.CrossRefPubMed
34.
Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S: Proteome-based plasma biomarkers for Alzheimer’s disease. Brain. 2006, 129: 3042-3050. 10.1093/brain/awl279.CrossRefPubMed
35.
Enticott PG, Kennedy HA, Rinehart NJ, Tonge BJ, Bradshaw JL, Fitzgerald PB: GABAergic activity in autism spectrum disorders: an investigation of cortical inhibition via transcranial magnetic stimulation. Neuropharmacology. 2013, 68: 202-209.CrossRefPubMed
36.
Blatt GJ: The neuropathology of autism. Scientifica (Cairo). 2012, 2012: 703675.
37.
Mendez MA, Horder J, Myers J, Coghlan S, Stokes P, Erritzoe D, Howes O, Lingford-Hughes A, Murphy D, Nutt D: The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study. Neuropharmacology. 2013, 68: 195-201.PubMedCentralCrossRefPubMed
38.
DeLorey TM, Handforth A, Anagnostaras SG, Homanics GE, Minassian BA, Asatourian A, Fanselow MS, Delgado-Escueta A, Ellison GD, Olsen RW: Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome. J Neurosci. 1998, 18 (20): 8505-8514.PubMed
39.
Colas D, Chuluun B, Warrier D, Blank M, Wetmore DZ, Buckmaster P, Garner CC, Heller HC: Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down’s syndrome. Br J Pharmacol. 2013, 169 (5): 963-973. 10.1111/bph.12169.PubMedCentralCrossRefPubMed
40.
Meneses A: 5-HT systems: emergent targets for memory formation and memory alterations. Rev Neurosci. 2013, 24 (6): 629-664.CrossRefPubMed
41.
Spivak B, Golubchik P, Mozes T, Vered Y, Nechmad A, Weizman A, Strous RD: Low platelet-poor plasma levels of serotonin in adult autistic patients. Neuropsychobiology. 2004, 50 (2): 157-160. 10.1159/000079108.CrossRefPubMed
42.
Mostafa GA, Al-Ayadhi LY: A lack of association between hyperserotonemia and the increased frequency of serum anti-myelin basic protein auto-antibodies in autistic children. J Neuroinflammation. 2011, 22 (8): 71.CrossRef
43.
Connors SL: Prenatal β2-adrenergic receptor signaling and autism: dysmaturation and retained fetal function. Autism Current Theories and Evidence. Edited by: Zimmerman AW. 2008, Totowa: Humana Press, 147-182.
44.
Marazziti D, Dell’Osso B, Baroni S, Vivarelli L, Masala F, Mungai F, Muratori F: The serotonin transporter is increased in platelets of autistic children. Trends in Autism Research. Edited by: Ryaskin OT. 2004, New York: Nova Science, 187-195.
45.
Gorton GE, Swirsky-Sacchetti T, Sobel R, Samuel S, Gordon A: Neuropsychology of childhood mental disorders: interaction of phenomenological, neurobiological, and neuropsychological findings. Assessment of Neuropsychological Functions in Psychiatric Disorders. Edited by: Avraham C. 1999, Washington DC: American Psychiatric Press, 135-233.
46.
Kuperman S, Beeghly JH, Burns TL, Tsai LY: Association of serotonin concentration to behavior and IQ in autistic children. J Autism Dev Disord. 1987, 17 (1): 133-140. 10.1007/BF01487265.CrossRefPubMed
47.
Gillberg C, Svennerholm L: CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. Br J Psychiatry. 1987, 151: 89-94. 10.1192/bjp.151.1.89.CrossRefPubMed
48.
Toda Y, Mori K, Hashimoto T, Miyazaki M, Nozaki S, Watanabe Y, Kuroda Y, Kagami S: Administration of secretin for autism alters dopamine metabolism in the central nervous system. Brain Dev. 2006, 28: 99-103. 10.1016/j.braindev.2005.05.005.CrossRefPubMed
49.
Previc FH: Prenatal influences on brain dopamine and their relevance to the rising incidence of autism. Medical Hypotheses. 2007, 68: 46-60. 10.1016/j.mehy.2006.06.041.CrossRefPubMed
50.
Narayan M, Srinath S, Anderson GM, Meundi DB: Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism. Biol Psychiatry. 1993, 33 (8–9): 630-635.CrossRefPubMed
51.
Field T, Diego M, Hernandez-Reif M, Figueiredo B, Deeds O, Ascencio A, Schanberg S: Cynthia Kuhn Prenatal dopamine and neonatal behavior and biochemistry. Infant Behav Dev. 2008, 31: 590-593. 10.1016/j.infbeh.2008.07.007.PubMedCentralCrossRefPubMed
52.
Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE: Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci. 2003, 23 (6): 2008-2013.PubMed
53.
Schouwenburg MV, Aarts E, Cools R: Dopaminergic modulation of cognitive control: distinct roles for the prefrontal cortex and the basal ganglia. Curr Pharm Des. 2010, 16: 2026-2032. 10.2174/138161210791293097.CrossRefPubMed
54.
Hamilton PJ, Campbell NG, Sharma S, Erreger K, Herborg Hansen F, Saunders C, Belovich AN, Sahai MA, Cook EH, Gether U, McHaourab HS, Matthies HJ, Sutcliffe JS, Galli A, NIH ARRA Autism Sequencing Consortium: De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder. Mol Psychiatry. 2013, 18: 1315-1323. 10.1038/mp.2013.102.PubMedCentralCrossRefPubMed
55.
Kaufman S, Friedman S: Dopamine β-hydroxylase. Pharmacol Rev. 1965, 17: 71-100.PubMed
56.
Elston RC, Namboodiri KK, Hames CG: Segregation and linkage analyses of dopamine-β-hydroxylase activity. Hum Hered. 1979, 29: 284-292. 10.1159/000153059.CrossRefPubMed
57.
Robinson PD, Schutz CK, Macciardi F, White BN, Holden JJA: Genetically determined low maternal serum dopamine β-hydroxylase levels and the etiology of autism spectrum disorders. Am J Med Genet. 2001, 100: 30-36. 10.1002/ajmg.1187.CrossRefPubMed
58.
Young LJ, Lim MM, Gingrich B, Insel TR: Cellular mechanisms of social attachment. Horm Behav. 2001, 40 (2): 133-138. 10.1006/hbeh.2001.1691.CrossRefPubMed
59.
Green L, Fein D, Modahl C, Feinstein C, Waterhouse L, Morris M: Oxytocin and autistic disorder: alterations in peptide forms. Biol Psychiatry. 2001, 50 (8): 609-613. 10.1016/S0006-3223(01)01139-8.CrossRefPubMed
60.
Lee HJ, Caldwell HK, Macbeth AH, Tolu SG, Young WS: A conditional knockout mouse line of the oxytocin receptor. Endocrinology. 2008, 149 (7): 3256-3263. 10.1210/en.2007-1710.PubMedCentralCrossRefPubMed
61.
Cao Y, Wu R, Tai F, Zhang X, Yu P, An X, Qiao X, Hao P: Neonatal paternal deprivation impairs social recognition and alters levels of oxytocin and estrogen receptor α mRNA expression in the MeA and NAcc, and serum oxytocin in mandarin voles. Horm Behav. 2014, 6: 57-65.CrossRef
62.
Lukas M, Neumann ID: Oxytocin and vasopressin in rodent behaviors related to social dysfunctions in autism spectrum disorders. Behav Brain Res. 2013, 251: 85-94.CrossRefPubMed
63.
Hoge EA, Pollack MH, Kaufman RE, Zak PJ, Simon NM: Oxytocin levels in social anxiety disorder. CNS Neurosci Ther. 2008, 14 (3): 165-170. 10.1111/j.1755-5949.2008.00051.x.CrossRefPubMed
64.
El-Masry N, Soliman A, Abdel Moety H: Alterations of prolyl endopeptidase, oxytocin and vasopressin activity in the plasma of autistic children. Current Psychiatry. 2010, 17 (1): 31-37.
65.
Yrigollen CM, Han SS, Kochetkova A, Babitz T, Chang JT, Volkmar FR, Leckman JF, Grigorenko EL: Genes controlling affiliative behavior as candidate genes for autism. Biol Psychiatry. 2008, 63: 911-916. 10.1016/j.biopsych.2007.11.015.PubMedCentralCrossRefPubMed
66.
Borden EC: Gene regulation and clinical roles for interferons in neoplastic diseases. Oncologist. 1998, 3: 198-203.PubMed
67.
Garcia-Sastre A, Biron CA: Type I interferons and the virus-host relationship: a lesson in détente. Science. 2006, 312: 879-882. 10.1126/science.1125676.CrossRefPubMed
68.
Conrady CD, Zheng M, Mandal NA, van Rooijen N, Carr DJ: IFN-α-driven CCL2 production recruits inflammatory monocytes to infection site in mice. Mucosal Immunol. 2013, 6 (1): 45-55. 10.1038/mi.2012.46.PubMedCentralCrossRefPubMed
69.
Garbett K, Ebert PJ, Mitchell A, Lintas C, Manzi B, Mirnics K, Persico AM: Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol Dis. 2008, 30 (3): 303-311. 10.1016/j.nbd.2008.01.012.PubMedCentralCrossRefPubMed
70.
Santana-de Anda K, Gómez-Martín D, Soto-Solís R, Alcocer-Varela J: Plasmacytoid dendritic cells: key players in viral infections and autoimmune diseases. Semin Arthritis Rheum. 2013, 43 (1): 131-136. 10.1016/j.semarthrit.2012.12.026.CrossRefPubMed
71.
Gugliesi F, Mondini M, Ravera R, Robotti A, de Andrea M, Gribaudo G, Gariglio M, Landolfo S: Up-regulation of the interferon-inducible IFI16 gene by oxidative stress triggers p53 transcriptional activity in endothelial cells. J LeukocBiol. 2005, 77 (5): 820-829.CrossRef
72.
Lam S, Li Q, Wei R, Zhang X, Chua S, McAlonan GM: Oxygen restriction of neonate rats elevates HIF-1a, IL-6, NF-kB and caspases-3 protein levels: possible relationship to neurodevelopmental disorders. Abstracts of the 3rd Biennial Schizophrenia Int Res Conf/Schizophr Res. 2012, 136 (Supplement 1): S1-S375.
73.
Malik M, Tauqeer Z, Sheikh AM, Wen G, Nagori A, Yang K, Brown WT, Li X: NF-κB signaling in the brain of autistic subjects. Mediators Inflamm. 2011, Article ID: 785265.
Metadata
Title
Association of social and cognitive impairment and biomarkers in autism spectrum disorders
Authors
Altaf Alabdali
Laila Al-Ayadhi
Afaf El-Ansary
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2014
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-11-4

Other articles of this Issue 1/2014

Journal of Neuroinflammation 1/2014 Go to the issue

Research

Longitudinal follow-up of autophagy and inflammation in brain of APPswePS1dE9 transgenic mice

Research

Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain

Research

Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition

Research

Chlamydia pneumoniae infection of monocytes in vitro stimulates innate and adaptive immune responses relevant to those in Alzheimer’s disease

Research

CD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis

Research

Metabolic consequences of interleukin-6 challenge in developing neurons and astroglia